Everest Medicines Reaffirms Revenue Guidance for the Year 2023 and 2024
The company is reaffirming revenue guidance for 2024 of RMB 700 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.64 HKD | +4.47% |
|
+2.51% | -6.03% |
1st Jan change | Capi. | |
---|---|---|
-6.03% | 772M | |
+5.37% | 97.06B | |
+6.18% | 41.54B | |
-8.83% | 33.89B | |
+83.27% | 29.78B | |
-13.01% | 15.63B | |
-0.84% | 13.66B | |
-12.22% | 11.43B | |
+174.11% | 10.37B | |
+4.64% | 9.14B |